Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yaowei Zhu"'
Autor:
Honghui Zhou, Wangda Zhou, Yaowei Zhu, Zhenhua Xu, Chuanpu Hu, Michael Song, Amarnath Sharma, Bruce Randazzo
Publikováno v:
Clinical pharmacology and therapeutics. 109(1)
Ustekinumab (STELARA) is a human monoclonal antibody against interleukins-12 and -23 for the treatment of adult and adolescent (≥ 12 to < 18 years of age) patients with moderate-to-severe plaque psoriasis. A phase III study was recently completed i
Autor:
Richard G. Langley, Newman Yeilding, Yaowei Zhu, Kim A. Papp, Y. Wang, Philippe Szapary, Shu Li, Kristian Reich, Mark Lebwohl
Publikováno v:
Journal of the American Academy of Dermatology. 63:571-579
Background Patients with psoriasis tend to be overweight, and the efficacy of fixed-dose biologics may be compromised by high body weight. Objective We sought to determine whether the optimal dose of ustekinumab is affected by weight in patients with
Publikováno v:
Journal of clinical pharmacology. 50(3)
Ustekinumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody that binds with high affinity to human interleukin-12 and interleukin-23, has demonstrated efficacy in patients with psoriasis. The objective of this study was to perform exposu
Autor:
René, Westhovens, Frédéric, Houssiau, Johan, Joly, Daniel E, Everitt, Yaowei, Zhu, Deborah, Sisco, Bart, Van Hartingsveldt, Mary Ann, Mascelli, Martin A, Graham, Patrick, Durez, Esther, Bouman-Thio
Publikováno v:
The Journal of rheumatology. 33(5)
To assess safety, clinical response, and pharmacokinetics of subcutaneous (SC) and intramuscular (IM) doses of an experimental formulation of infliximab [including experimental SC doses following administration of commercially-formulated intravenous
Autor:
Alan Menter, Colleen Marano, Amy S. Paller, Ming Chun Hsu, Ian Landells, Bruce Randazzo, Lawrence F. Eichenfield, Shu Li, Alain Taieb, Sandra Philipp, Yaowei Zhu, Peter H. Hoeger, Philippe Szapary
Publikováno v:
Journal of the American Academy of Dermatology. (4):594-603
BackgroundSafe and effective therapies are needed for pediatric patients with psoriasis.ObjectiveThe purpose of this study was to evaluate ustekinumab in patients age 12 to 17 years who had moderate-to-severe psoriasis.MethodsPatients (n = 110) were